Global Til Therapy- Market
Global Til Therapy- Market

Til Therapy- Comprehensive Study by Type (Single Injection, Multiple Injections), Application (Stomach Cancer, Cancer of Pancreas, Hepatoma, Uterine/Endometrial Carcinoma, Cervical Carcinoma, Urethral Carcinoma, Renal-cell Carcinoma, Other) Players and Region - Global Market Outlook to 2026

Til Therapy- Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2022 Edition 220 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Til Therapy-?
TIL therapy is a type of adoptive cellular treatment that involves extracting infiltrated lymphocytes from tumours, cultivating and multiplying them in vitro, and then infusing them back into patients to treat them. TIL therapy has distinct advantages in treating solid tumours over other adoptive cellular therapies because of its diversified TCR clonality, greater tumor-homing capacity, and less off-target damage. TIL is extracted from the tumour site via biopsy or surgery, activated and grown in vitro with interleukin-2 (IL-2), and then returned to the patient.

The market study is broken down by Type (Single Injection and Multiple Injections), by Application (Stomach Cancer, Cancer of Pancreas, Hepatoma, Uterine/Endometrial Carcinoma, Cervical Carcinoma, Urethral Carcinoma, Renal-cell Carcinoma and Other) and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Til Therapy- market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Iovance Biotherapeutics Inc. (United States), Adaptimmune Therapeutics Plc. (United Kingdom), Achilles Therapeutics Ltd. (United Kingdom), Intima Bioscience Inc. (New York), Nurix Therapeutics Inc (United States), KSQ Therapeutics Inc. (United States), Obsidian Therapeutics Inc. (United States), PACT Pharma Inc. (United States), Neogene Therapeutics (Netherlands) and Instil Bio Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Til Therapy- market by Type, Application and Region.

On the basis of geography, the market of Til Therapy- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In 2021, Instil Bio, Inc. a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations demonstrating pre-clinical data of the CoStimulatory Antigen Receptor platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, held from November 10-14, 2021. Instil also presented a Trials-in-Progress poster detailing DELTA-1, the ongoing Phase 2 study of ITIL-168 in advanced melanoma.


Market Trend
  • Growing Technological Advancements in the Manufacturing Process

Market Drivers
  • Rising Prevalence of Cancer

Opportunities
  • Development of Healthcare Infrastructure

Restraints
  • High Costs Associated with Til Therapy
  • Side Effects

Challenges
  • Developing Effective Adoptive Cellular Therapies


Key Target Audience
New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as Iovance Biotherapeutics Inc. (United States), Adaptimmune Therapeutics Plc. (United Kingdom), Achilles Therapeutics Ltd. (United Kingdom), Intima Bioscience Inc. (New York), Nurix Therapeutics Inc (United States), KSQ Therapeutics Inc. (United States), Obsidian Therapeutics Inc. (United States), PACT Pharma Inc. (United States), Neogene Therapeutics (Netherlands) and Instil Bio Inc. (United States) etc.

2. Can we have customized study for Til Therapy- Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Til Therapy- Market by 2026?
Analysts at AMA estimates Til Therapy- Market to reach USD Million by 2026.
Report Objectives / Segmentation Covered
By Type
  • Single Injection
  • Multiple Injections
By Application
  • Stomach Cancer
  • Cancer of Pancreas
  • Hepatoma
  • Uterine/Endometrial Carcinoma
  • Cervical Carcinoma
  • Urethral Carcinoma
  • Renal-cell Carcinoma
  • Other
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cancer
    • 3.3. Market Challenges
      • 3.3.1. Developing Effective Adoptive Cellular Therapies
    • 3.4. Market Trends
      • 3.4.1. Growing Technological Advancements in the Manufacturing Process
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Til Therapy-, by Type, Application and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Til Therapy- (Value)
      • 5.2.1. Global Til Therapy- by: Type (Value)
        • 5.2.1.1. Single Injection
        • 5.2.1.2. Multiple Injections
      • 5.2.2. Global Til Therapy- by: Application (Value)
        • 5.2.2.1. Stomach Cancer
        • 5.2.2.2. Cancer of Pancreas
        • 5.2.2.3. Hepatoma
        • 5.2.2.4. Uterine/Endometrial Carcinoma
        • 5.2.2.5. Cervical Carcinoma
        • 5.2.2.6. Urethral Carcinoma
        • 5.2.2.7. Renal-cell Carcinoma
        • 5.2.2.8. Other
      • 5.2.3. Global Til Therapy- Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Til Therapy-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Iovance Biotherapeutics Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Adaptimmune Therapeutics Plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Achilles Therapeutics Ltd. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Intima Bioscience Inc. (New York)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nurix Therapeutics Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. KSQ Therapeutics Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Obsidian Therapeutics Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. PACT Pharma Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Neogene Therapeutics (Netherlands)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Instil Bio Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Til Therapy- Sale, by Type, Application and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Til Therapy- (Value)
      • 7.2.1. Global Til Therapy- by: Type (Value)
        • 7.2.1.1. Single Injection
        • 7.2.1.2. Multiple Injections
      • 7.2.2. Global Til Therapy- by: Application (Value)
        • 7.2.2.1. Stomach Cancer
        • 7.2.2.2. Cancer of Pancreas
        • 7.2.2.3. Hepatoma
        • 7.2.2.4. Uterine/Endometrial Carcinoma
        • 7.2.2.5. Cervical Carcinoma
        • 7.2.2.6. Urethral Carcinoma
        • 7.2.2.7. Renal-cell Carcinoma
        • 7.2.2.8. Other
      • 7.2.3. Global Til Therapy- Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Til Therapy-: by Type(USD Million)
  • Table 2. Til Therapy- Single Injection , by Region USD Million (2015-2020)
  • Table 3. Til Therapy- Multiple Injections , by Region USD Million (2015-2020)
  • Table 4. Til Therapy-: by Application(USD Million)
  • Table 5. Til Therapy- Stomach Cancer , by Region USD Million (2015-2020)
  • Table 6. Til Therapy- Cancer of Pancreas , by Region USD Million (2015-2020)
  • Table 7. Til Therapy- Hepatoma , by Region USD Million (2015-2020)
  • Table 8. Til Therapy- Uterine/Endometrial Carcinoma , by Region USD Million (2015-2020)
  • Table 9. Til Therapy- Cervical Carcinoma , by Region USD Million (2015-2020)
  • Table 10. Til Therapy- Urethral Carcinoma , by Region USD Million (2015-2020)
  • Table 11. Til Therapy- Renal-cell Carcinoma , by Region USD Million (2015-2020)
  • Table 12. Til Therapy- Other , by Region USD Million (2015-2020)
  • Table 13. South America Til Therapy-, by Country USD Million (2015-2020)
  • Table 14. South America Til Therapy-, by Type USD Million (2015-2020)
  • Table 15. South America Til Therapy-, by Application USD Million (2015-2020)
  • Table 16. Brazil Til Therapy-, by Type USD Million (2015-2020)
  • Table 17. Brazil Til Therapy-, by Application USD Million (2015-2020)
  • Table 18. Argentina Til Therapy-, by Type USD Million (2015-2020)
  • Table 19. Argentina Til Therapy-, by Application USD Million (2015-2020)
  • Table 20. Rest of South America Til Therapy-, by Type USD Million (2015-2020)
  • Table 21. Rest of South America Til Therapy-, by Application USD Million (2015-2020)
  • Table 22. Asia Pacific Til Therapy-, by Country USD Million (2015-2020)
  • Table 23. Asia Pacific Til Therapy-, by Type USD Million (2015-2020)
  • Table 24. Asia Pacific Til Therapy-, by Application USD Million (2015-2020)
  • Table 25. China Til Therapy-, by Type USD Million (2015-2020)
  • Table 26. China Til Therapy-, by Application USD Million (2015-2020)
  • Table 27. Japan Til Therapy-, by Type USD Million (2015-2020)
  • Table 28. Japan Til Therapy-, by Application USD Million (2015-2020)
  • Table 29. India Til Therapy-, by Type USD Million (2015-2020)
  • Table 30. India Til Therapy-, by Application USD Million (2015-2020)
  • Table 31. South Korea Til Therapy-, by Type USD Million (2015-2020)
  • Table 32. South Korea Til Therapy-, by Application USD Million (2015-2020)
  • Table 33. Taiwan Til Therapy-, by Type USD Million (2015-2020)
  • Table 34. Taiwan Til Therapy-, by Application USD Million (2015-2020)
  • Table 35. Australia Til Therapy-, by Type USD Million (2015-2020)
  • Table 36. Australia Til Therapy-, by Application USD Million (2015-2020)
  • Table 37. Rest of Asia-Pacific Til Therapy-, by Type USD Million (2015-2020)
  • Table 38. Rest of Asia-Pacific Til Therapy-, by Application USD Million (2015-2020)
  • Table 39. Europe Til Therapy-, by Country USD Million (2015-2020)
  • Table 40. Europe Til Therapy-, by Type USD Million (2015-2020)
  • Table 41. Europe Til Therapy-, by Application USD Million (2015-2020)
  • Table 42. Germany Til Therapy-, by Type USD Million (2015-2020)
  • Table 43. Germany Til Therapy-, by Application USD Million (2015-2020)
  • Table 44. France Til Therapy-, by Type USD Million (2015-2020)
  • Table 45. France Til Therapy-, by Application USD Million (2015-2020)
  • Table 46. Italy Til Therapy-, by Type USD Million (2015-2020)
  • Table 47. Italy Til Therapy-, by Application USD Million (2015-2020)
  • Table 48. United Kingdom Til Therapy-, by Type USD Million (2015-2020)
  • Table 49. United Kingdom Til Therapy-, by Application USD Million (2015-2020)
  • Table 50. Netherlands Til Therapy-, by Type USD Million (2015-2020)
  • Table 51. Netherlands Til Therapy-, by Application USD Million (2015-2020)
  • Table 52. Rest of Europe Til Therapy-, by Type USD Million (2015-2020)
  • Table 53. Rest of Europe Til Therapy-, by Application USD Million (2015-2020)
  • Table 54. MEA Til Therapy-, by Country USD Million (2015-2020)
  • Table 55. MEA Til Therapy-, by Type USD Million (2015-2020)
  • Table 56. MEA Til Therapy-, by Application USD Million (2015-2020)
  • Table 57. Middle East Til Therapy-, by Type USD Million (2015-2020)
  • Table 58. Middle East Til Therapy-, by Application USD Million (2015-2020)
  • Table 59. Africa Til Therapy-, by Type USD Million (2015-2020)
  • Table 60. Africa Til Therapy-, by Application USD Million (2015-2020)
  • Table 61. North America Til Therapy-, by Country USD Million (2015-2020)
  • Table 62. North America Til Therapy-, by Type USD Million (2015-2020)
  • Table 63. North America Til Therapy-, by Application USD Million (2015-2020)
  • Table 64. United States Til Therapy-, by Type USD Million (2015-2020)
  • Table 65. United States Til Therapy-, by Application USD Million (2015-2020)
  • Table 66. Canada Til Therapy-, by Type USD Million (2015-2020)
  • Table 67. Canada Til Therapy-, by Application USD Million (2015-2020)
  • Table 68. Mexico Til Therapy-, by Type USD Million (2015-2020)
  • Table 69. Mexico Til Therapy-, by Application USD Million (2015-2020)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Til Therapy-: by Type(USD Million)
  • Table 81. Til Therapy- Single Injection , by Region USD Million (2021-2026)
  • Table 82. Til Therapy- Multiple Injections , by Region USD Million (2021-2026)
  • Table 83. Til Therapy-: by Application(USD Million)
  • Table 84. Til Therapy- Stomach Cancer , by Region USD Million (2021-2026)
  • Table 85. Til Therapy- Cancer of Pancreas , by Region USD Million (2021-2026)
  • Table 86. Til Therapy- Hepatoma , by Region USD Million (2021-2026)
  • Table 87. Til Therapy- Uterine/Endometrial Carcinoma , by Region USD Million (2021-2026)
  • Table 88. Til Therapy- Cervical Carcinoma , by Region USD Million (2021-2026)
  • Table 89. Til Therapy- Urethral Carcinoma , by Region USD Million (2021-2026)
  • Table 90. Til Therapy- Renal-cell Carcinoma , by Region USD Million (2021-2026)
  • Table 91. Til Therapy- Other , by Region USD Million (2021-2026)
  • Table 92. South America Til Therapy-, by Country USD Million (2021-2026)
  • Table 93. South America Til Therapy-, by Type USD Million (2021-2026)
  • Table 94. South America Til Therapy-, by Application USD Million (2021-2026)
  • Table 95. Brazil Til Therapy-, by Type USD Million (2021-2026)
  • Table 96. Brazil Til Therapy-, by Application USD Million (2021-2026)
  • Table 97. Argentina Til Therapy-, by Type USD Million (2021-2026)
  • Table 98. Argentina Til Therapy-, by Application USD Million (2021-2026)
  • Table 99. Rest of South America Til Therapy-, by Type USD Million (2021-2026)
  • Table 100. Rest of South America Til Therapy-, by Application USD Million (2021-2026)
  • Table 101. Asia Pacific Til Therapy-, by Country USD Million (2021-2026)
  • Table 102. Asia Pacific Til Therapy-, by Type USD Million (2021-2026)
  • Table 103. Asia Pacific Til Therapy-, by Application USD Million (2021-2026)
  • Table 104. China Til Therapy-, by Type USD Million (2021-2026)
  • Table 105. China Til Therapy-, by Application USD Million (2021-2026)
  • Table 106. Japan Til Therapy-, by Type USD Million (2021-2026)
  • Table 107. Japan Til Therapy-, by Application USD Million (2021-2026)
  • Table 108. India Til Therapy-, by Type USD Million (2021-2026)
  • Table 109. India Til Therapy-, by Application USD Million (2021-2026)
  • Table 110. South Korea Til Therapy-, by Type USD Million (2021-2026)
  • Table 111. South Korea Til Therapy-, by Application USD Million (2021-2026)
  • Table 112. Taiwan Til Therapy-, by Type USD Million (2021-2026)
  • Table 113. Taiwan Til Therapy-, by Application USD Million (2021-2026)
  • Table 114. Australia Til Therapy-, by Type USD Million (2021-2026)
  • Table 115. Australia Til Therapy-, by Application USD Million (2021-2026)
  • Table 116. Rest of Asia-Pacific Til Therapy-, by Type USD Million (2021-2026)
  • Table 117. Rest of Asia-Pacific Til Therapy-, by Application USD Million (2021-2026)
  • Table 118. Europe Til Therapy-, by Country USD Million (2021-2026)
  • Table 119. Europe Til Therapy-, by Type USD Million (2021-2026)
  • Table 120. Europe Til Therapy-, by Application USD Million (2021-2026)
  • Table 121. Germany Til Therapy-, by Type USD Million (2021-2026)
  • Table 122. Germany Til Therapy-, by Application USD Million (2021-2026)
  • Table 123. France Til Therapy-, by Type USD Million (2021-2026)
  • Table 124. France Til Therapy-, by Application USD Million (2021-2026)
  • Table 125. Italy Til Therapy-, by Type USD Million (2021-2026)
  • Table 126. Italy Til Therapy-, by Application USD Million (2021-2026)
  • Table 127. United Kingdom Til Therapy-, by Type USD Million (2021-2026)
  • Table 128. United Kingdom Til Therapy-, by Application USD Million (2021-2026)
  • Table 129. Netherlands Til Therapy-, by Type USD Million (2021-2026)
  • Table 130. Netherlands Til Therapy-, by Application USD Million (2021-2026)
  • Table 131. Rest of Europe Til Therapy-, by Type USD Million (2021-2026)
  • Table 132. Rest of Europe Til Therapy-, by Application USD Million (2021-2026)
  • Table 133. MEA Til Therapy-, by Country USD Million (2021-2026)
  • Table 134. MEA Til Therapy-, by Type USD Million (2021-2026)
  • Table 135. MEA Til Therapy-, by Application USD Million (2021-2026)
  • Table 136. Middle East Til Therapy-, by Type USD Million (2021-2026)
  • Table 137. Middle East Til Therapy-, by Application USD Million (2021-2026)
  • Table 138. Africa Til Therapy-, by Type USD Million (2021-2026)
  • Table 139. Africa Til Therapy-, by Application USD Million (2021-2026)
  • Table 140. North America Til Therapy-, by Country USD Million (2021-2026)
  • Table 141. North America Til Therapy-, by Type USD Million (2021-2026)
  • Table 142. North America Til Therapy-, by Application USD Million (2021-2026)
  • Table 143. United States Til Therapy-, by Type USD Million (2021-2026)
  • Table 144. United States Til Therapy-, by Application USD Million (2021-2026)
  • Table 145. Canada Til Therapy-, by Type USD Million (2021-2026)
  • Table 146. Canada Til Therapy-, by Application USD Million (2021-2026)
  • Table 147. Mexico Til Therapy-, by Type USD Million (2021-2026)
  • Table 148. Mexico Til Therapy-, by Application USD Million (2021-2026)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Til Therapy-: by Type USD Million (2015-2020)
  • Figure 5. Global Til Therapy-: by Application USD Million (2015-2020)
  • Figure 6. South America Til Therapy- Share (%), by Country
  • Figure 7. Asia Pacific Til Therapy- Share (%), by Country
  • Figure 8. Europe Til Therapy- Share (%), by Country
  • Figure 9. MEA Til Therapy- Share (%), by Country
  • Figure 10. North America Til Therapy- Share (%), by Country
  • Figure 11. Global Til Therapy- share by Players 2020 (%)
  • Figure 12. Global Til Therapy- share by Players (Top 3) 2020(%)
  • Figure 13. Global Til Therapy- share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Iovance Biotherapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Iovance Biotherapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 17. Adaptimmune Therapeutics Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Adaptimmune Therapeutics Plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Achilles Therapeutics Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Achilles Therapeutics Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 21. Intima Bioscience Inc. (New York) Revenue, Net Income and Gross profit
  • Figure 22. Intima Bioscience Inc. (New York) Revenue: by Geography 2020
  • Figure 23. Nurix Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Nurix Therapeutics Inc (United States) Revenue: by Geography 2020
  • Figure 25. KSQ Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. KSQ Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Obsidian Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Obsidian Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 29. PACT Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. PACT Pharma Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Neogene Therapeutics (Netherlands) Revenue, Net Income and Gross profit
  • Figure 32. Neogene Therapeutics (Netherlands) Revenue: by Geography 2020
  • Figure 33. Instil Bio Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Instil Bio Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Global Til Therapy-: by Type USD Million (2021-2026)
  • Figure 36. Global Til Therapy-: by Application USD Million (2021-2026)
  • Figure 37. South America Til Therapy- Share (%), by Country
  • Figure 38. Asia Pacific Til Therapy- Share (%), by Country
  • Figure 39. Europe Til Therapy- Share (%), by Country
  • Figure 40. MEA Til Therapy- Share (%), by Country
  • Figure 41. North America Til Therapy- Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Iovance Biotherapeutics Inc. (United States)
  • Adaptimmune Therapeutics Plc. (United Kingdom)
  • Achilles Therapeutics Ltd. (United Kingdom)
  • Intima Bioscience Inc. (New York)
  • Nurix Therapeutics Inc (United States)
  • KSQ Therapeutics Inc. (United States)
  • Obsidian Therapeutics Inc. (United States)
  • PACT Pharma Inc. (United States)
  • Neogene Therapeutics (Netherlands)
  • Instil Bio Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation